Evidence map›Paper›PMID 40813768›Full record

ArticleSignal transduction and targeted therapy2025

DNA/RNA-binding protein KIN17 supports esophageal cancer progression via resolving noncanonical STING activation induced by R-loop.

Zichao Wei, Ning Zhao, Lu Kuang, Ji Cong, Sujuan Zheng, Yi Li, Zhihua Liu

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zichao Wei *State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
Ning Zhao *State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
Lu KuangState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
Ji CongState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
Sujuan ZhengState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
Yi LiState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China. liyi@cicams.ac.cn.
Zhihua LiuState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China. liuzh@cicams.ac.cn.ORCID 0000-0003-4242-033X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting the DNA damage response (DDR) exhibits potent efficacy in inducing immune activation and enhancing patient prognosis. However, the benefits of DDR regulation are not universally observed across all patients, owing to the intricate compensatory mechanisms operative in certain cancers. There still exists a gap in the function of activated DDR protein in esophageal squamous cell carcinoma (ESCC). Here, we demonstrate that increased expression of DDR genes contributes to the progression of esophageal squamous cell carcinoma and suppresses the tumor immune microenvironment. Notably, the abundant presence of the DDR protein KIN in ESCC tissues facilitates efficient DNA damage clearance and promotes escape from apoptosis. Depletion of KIN significantly inhibited proliferation and induced DNA damage accumulation in ESCC cells. Mechanistically, KIN functions to support the recruitment of the R-loop regulator DHX9 to R-loop sites, thereby addressing DNA damage associated R-loops. Intriguingly, the depletion of KIN activates the STING pathway via NFκB signaling, which is induced by the accumulation of R-loops, ultimately initiating an innate immune response. Depletion of KIN improved the immune microenvironment and the effect of immune therapy in mouse model. Collectively, our findings identify KIN as a novel R-loop binding protein that facilitates the recruitment of the R-loop resolution complex and suppresses tumor-intrinsic innate immunity.

Indexed as

DNA-Binding ProteinsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaMembrane ProteinsRNA-Binding ProteinsAnimalsCell Line, TumorCell ProliferationDisease ProgressionDNA DamageGene Expression Regulation, NeoplasticHumansMiceSignal TransductionSTING ProteinTumor MicroenvironmentDNA-Binding ProteinsMembrane ProteinsRNA-Binding ProteinsSTING1 protein, humanSTING Protein

Identifiers

PMID40813768
PMCPMC12354822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.